Oncology Research

 
Stock Quotes for Oncology Research top ^
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Type: Speculative Growth
Sign-up for csbr investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Large Growth
  • Stock Type: Speculative Growth
Sign-up for csbr investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Core
  • Stock Type: Speculative Growth
Sign-up for ziop investment picks
  • Industry: Diagnostics & Research
  • Sector: Healthcare
  • Stock Type: Distressed
Sign-up for avto investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Distressed
Sign-up for clvs investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Core
  • Stock Type: Speculative Growth
Sign-up for ziop investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Distressed
Sign-up for clvs investment picks
  • Industry: Medical Care
  • Sector: Healthcare
  • Stock Type: Distressed
Sign-up for roix investment picks

 
News Articles for Oncology Research top ^
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that, subject to market and other conditions, it intends to offer $200 million aggregate principal amount of its convertible senior notes due 2021 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Sign-up for Clovis Oncology to Offer $200 Million of Convertible Senior Notes investment picks
Charleston Area Medical Center (CAMC) and Charleston Radiation Therapy Consultants are working with Alliance Oncology, a division of Alliance HealthCare Services, to establish a department of radiation therapy at the CAMC Cancer Center.
Sign-up for Charleston Area Medical Center and Alliance Oncology Set to Establish a New Radiation Therapy Department at CAMC Cancer Center investment picks
BOSTON and TOKYO, July 31, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. ("ZIOPHARM") (Nasdaq:ZIOP) , a biopharmaceutical company focused on the development and commercialization of new cancer therapies, and Solasia Pharma K.K. ("Solasia"), a developer of oncology pharmaceuticals in-licensed for commercialization in major markets throughout the world, announced today an amendment and restatement of their License and Collaboration Agreement for darinaparsin (Zinapar™ or ZIO-101) and related organoarsenic molecules.
Sign-up for ZIOPHARM Oncology and Solasia Pharma Announce Global License and Collaboration Agreement for Darinaparsin investment picks
Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for its third quarter ended September 30, 2014, and provided an update on the Company’s clinical development programs for the rest of 2014.
Sign-up for Clovis Oncology Announces Third Quarter 2014 Operating Results investment picks
The state of West Virginia has approved the Certificate of Need (CON) filed by the Charleston Area Medical Center (CAMC), Charleston Radiation Therapy Consultants, and Alliance Oncology, a division of Alliance HealthCare Services—enabling the joint venture to assume management and operations of the department of radiation therapy at the CAMC Cancer Center.
Sign-up for Charleston Area Medical Center and Alliance Oncology Receive State Approval for New Radiation Therapy Department investment picks
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the initial purchasers of the previously announced offering of the Company’s 2.50% Convertible Senior Notes due 2021 (the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, have elected to exercise in full their option to purchase an additional $37.5 million aggregate principal amount of the Notes.
Sign-up for Clovis Oncology Announces Exercise in Full by Initial Purchasers of Their Option to Purchase an Additional $37.5 Million Aggregate Principal Amount of the Company’s 2.50% Convertible Senior Notes Due 2021 investment picks
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that its global Phase 2 study of lucitanib in patients with FGFR1-amplified squamous non-small cell lung cancer (NSCLC) has commenced and the first patient has been dosed at a U.S. study site.
Sign-up for Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer investment picks
Clovis Oncology (NASDAQ:CLVS) today announced that its Phase 2 study of lucitanib in patients with FGF-aberrant, advanced breast cancer has commenced and the first patient dosed at a U.S. study site.
Sign-up for Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in FGF-aberrant Advanced Breast Cancer investment picks
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.
Sign-up for Clovis Oncology to Present at the 2014 Morgan Stanley Global Healthcare Conference investment picks
STAMFORD, Conn., Sept.
Sign-up for Loxo Oncology Announces Second Quarter 2014 Financial Results investment picks
AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the European Society for Medical Oncology (ESMO), taking place September 25–30 in Madrid, Spain.
Sign-up for AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced Colorectal and Kidney Cancers Presented at ESMO 2014 Congress investment picks
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2014 financial results on Thursday, November 6, 2014, after the close of the U.S. financial markets.
Sign-up for Clovis Oncology to Announce Third Quarter 2014 Financial Results and Host Webcast Conference Call on November 6 investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Oncology Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: On-Year Growth  |  Next: One Holding